ArticleDiscover oncology2025
Pan-cancer analysis and experimental validation revealed the prognostic role of ZNF83 in renal and lung cancer cohorts.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioinformatics analysis of potential molecular markers and immunological characteristics shared between post-treatment Lyme disease syndrome and rheumatoid arthritis.Frontiers in immunology · 2026Article
- Zinc finger protein 514 promotes esophageal cancer progression by enhancing cell proliferation, migration and invasion.Molecular medicine reports · 2026Article
- Pan-cancer analysis and experimental verification of its roles and clinical significance of SLC2A3 in kidney renal clear cell carcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAbnormal expression of zinc finger (ZNF) proteins is closely associated with tumor proliferation and metastasis. However, due to limited knowledge about ZNF83, we conducted a pan-cancer analysis to explore its shared and distinct roles across various human malignancies.
methodStandardized TCGA pan-cancer data, encompassing clinical details and ZNF83 expression levels, were obtained for in-depth analysis. We assessed the expression landscape of ZNF83, explored its prognostic significance, and examined its relationship with tumor heterogeneity and cellular stemness. Furthermore, immunohistochemical analysis was performed on lung and kidney cancer tissues to support the bioinformatic findings.
resultsZNF83 expression patterns vary markedly among tumor types, with transcriptomic analysis revealing upregulation in eight malignancies and significant downregulation in twenty-two, compared to adjacent non-cancerous tissues. Notably, ZNF83 levels exhibited robust associations with markers indicative of genomic instability and with indices of tumor stemness across multiple cancer types, suggesting a role in genome maintenance and cellular plasticity. Immunohistochemical staining further substantiated these findings, showing elevated ZNF83 protein levels in renal carcinoma samples, whereas reduced expression was observed in lung adenocarcinoma specimens. In renal cancer, higher ZNF83 expression correlated with poorer overall survival, reinforcing its prognostic value. Although the difference in lung adenocarcinoma was not statistically significant, the expression trend was consistent with transcriptomic observations from the TCGA database.
conclusionZNF83 is differentially expressed across cancers and predicts poor prognosis, particularly in renal cell carcinoma, highlighting its utility as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.